The publication of positive data from a multicenter study is likely to be viewed favorably by investors and could lead to increased adoption of the SpinalStim device. This may result in higher sales and revenue for Orthofix, positively impacting the stock price in the short term. The study's focus on patients at risk of pseudarthrosis, a condition that can complicate spinal fusion surgeries, highlights the device's potential benefits in a challenging patient population, which could further drive demand.